Sign in

TCRT on Nasdaq

ZIOPHARM Oncology

Publicly held, clinical-stage biopharmaceutical company, based in Boston, founded in 20051

In its 2026 annual report the company says: “We are a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). We were previously a clinical-stage oncology-focused cell therapy company developing adoptive TCR-T cell therapies. We have not generated any product revenue and have incurred significant net losses in each year since our inception.”4 Its shares trade on Nasdaq under the symbol TCRT.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Jan 1, 2005Founded1

Compare with Processa Pharmaceuticals, Inc., One World Products, Inc. or Aspire-Lakewood Holdings, Inc., or pick any stock.

  • TickerTCRT on Nasdaq1
  • Industrypharmaceutical industry1
  • HeadquartersBoston1
  • Websitewww.ziopharm.com
  • Incorporated inDE3
  • Business address501 E Las Olas Blvd, Suite 300, Fort Lauderdale, Fl 333013
  • Filer categoryNon-accelerated filer, Smaller reporting company3

See how the biggest companies compare on our leaderboards

We are a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. On March 2, 2026, we announced positive preclinical proof-of-concept data for ALN1003 from two separate studies using a standard diet-induced obesity (DIO) mouse model in male C57BL/6 mice maintained on a high-fat diet (60% of calories from fat). Highlights from these studies include dose-dependent body weight loss with favorable body composition changes, reductions in liver weight, improvement in liver function biomarkers, and improvement in metabolic biomarkers. Collective…4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-84500.0%Operating margin5
-83520.0%Net margin5
-50.0%Revenue growth, 20255
-194.0%Return on equity5
-$3.0MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development100¢$1.4M

Out of $5.0K in revenue.5 The company lost money this year.

Financial statements

Revenue67895$5.0K in 2025
0$1.0M$2.0M$3.0M2020: $0$020202021: $398.0K$398.0K20212022: $2.9M$2.9M2022+634%2023: $5.0K$5.0K2023−100%2024: $10.0K$10.0K2024+100%2025: $5.0K$5.0K2025−50%
Operating income1067895-$4.2M in 2025−93% since 2019
-$100.0M-$75.0M-$50.0M-$25.0M02019: -$57.9M-$57.9M20192020: -$80.4M-$80.4M2020+39%2021: -$77.5M-$77.5M2021−3%2022: -$35.1M-$35.1M2022−55%2023: -$34.3M-$34.3M2023−2%2024: -$4.8M-$4.8M2024−86%2025: -$4.2M-$4.2M2025−12%
Net income106785-$4.2M in 2025−96% since 2019
-$150.0M-$100.0M-$50.0M02019: -$117.8M-$117.8M20192020: -$80.0M-$80.0M2020−32%2021: -$78.8M-$78.8M2021−2%2022: -$37.7M-$37.7M2022−52%2023: -$4.7M-$4.7M2023−88%2024: -$4.7M-$4.7M2024+0%2025: -$4.2M-$4.2M2025−11%

Every line of the income statement as filed: the last 3 fiscal years, latest first.5

Period ending2025-12-312024-12-312023-12-31
Revenue$5.0K$10.0K
Research and development$1.4M$362.0K
General and administrative$2.9M$4.5M
Total operating expenses$4.2M$4.8M
Loss from operations-$4.2M-$4.8M
Change in fair value of warrant liability-$31.0K$0
Other income , net$80.0K$133.0K
Other income (expense), net$49.0K$133.0K
Net loss-$4.2M-$4.7M-$4.7M
Earnings per share, Basic-$2.20-$2.92
Earnings per share, Diluted-$2.20-$2.92
Weighted average common shares outstanding, basic1.9M shares1.6M shares
Weighted average common shares outstanding, diluted1.9M shares1.6M shares

Compare ZIOPHARM Oncology with another company

Corporate structure

ZIOPHARM Oncology sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of ZIOPHARM Oncology

  • Fairmount Funds Management LLC Filed SCHEDULE 13D on ZIOPHARM Oncology, latest Oct 15, 2026
  • Robert W. Postma Filed SCHEDULE 13D/A on ZIOPHARM Oncology, latest Oct 15, 2026 (2 filings since Jul 1, 2025)
  • Adrian Price Filed SCHEDULE 13D/A on ZIOPHARM Oncology, latest Mar 5, 2026 (5 filings since Oct 30, 2025)
  • Strategic EP, LLC Filed SCHEDULE 13G/A on ZIOPHARM Oncology, latest Oct 16, 2025 (2 filings since Sep 4, 2025)
  • PMGC CAPITAL LLC Filed SCHEDULE 13D/A on ZIOPHARM Oncology, latest Sep 5, 2025 (2 filings since May 14, 2025)
  • MSD Partners, L.P. Filed SCHEDULE 13G/A on ZIOPHARM Oncology, latest Feb 13, 2025 (4 filings since Feb 14, 2023)
  • DISCOVERY CAPITAL MANAGEMENT, LLC / CT Filed SC 13G/A on ZIOPHARM Oncology, latest Feb 14, 2024 (3 filings since Feb 14, 2022)
  • VANGUARD GROUP INC Filed SC 13G/A on ZIOPHARM Oncology, latest Feb 9, 2023 (2 filings since Feb 10, 2022)
  • State Street Corporation Filed SC 13G/A on ZIOPHARM Oncology, latest Jan 20, 2023 (2 filings since Feb 11, 2022)
  • BlackRock Filed SC 13G on ZIOPHARM Oncology, latest Jul 8, 2022 (2 filings since Feb 3, 2022)
  • Robert D. Hardie Filed SC 13G/A on ZIOPHARM Oncology, latest Feb 11, 2022
  • MILLER VALUE PARTNERS, LLC Filed SC 13G/A on ZIOPHARM Oncology, latest Oct 12, 2021
  • ZIOPHARM Oncology Boston

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What ZIOPHARM Oncology reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$98.0K5 Dec 31, 2025$15.0K5 Dec 31, 2024+553.3%
Accumulated depreciation$7.0K5 Dec 31, 2025$15.0K5 Dec 31, 2024−53.3%
Property and equipment, net$91.0K5 Dec 31, 2025$05 Dec 31, 2024

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$1.4M5 Dec 31, 2025$1.1M5 Dec 31, 2024+26.9%

Properties, in its own words

Our corporate office is located at 501 E. Las Olas Blvd., Suite 300 Fort Lauderdale, FL 33301. We believe that our existing facilities are adequate to meet our current needs.

Item 2 of the 10-K filed Mar 31, 2026.4

Leadership

Who has led ZIOPHARM Oncology, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Laurence James Neil Cooper2015–2021
  2. Heidi Hagen2021
  3. Kevin S. Boyle Sr.2021–2023
  4. Dale Curtis Hogue Jr.2024
  5. Holger Weis2025–now

President

  1. Richard E. Bagley2006–2012
  2. Hagop Youssoufian2013
  3. David M. Mauney Md.2019–2020
  4. Laurence James Neil Cooper2021

Chief financial officer

  1. Jason Amello2012–2013
  2. Sath Shukla2019–2020
  3. Timothy M. Cunningham2021

Chief operating officer

  1. Richard E. Bagley2006–2012
  2. Caesar J. Belbel2015–2018
2010201520202025
Board members and other officers (39)

Former names

  • ZIOPHARM ONCOLOGY INCSep 20, 2005 to Jan 4, 20223
  • EASYWEB INCFeb 13, 2001 to Sep 19, 20053

Timeline

  1. Oct 13, 20268-K Entered a material agreement; Completed an acquisition or sale; Unregistered sale of shares63
  2. Oct 9, 20268-K Listing notice or transfer64
  3. Sep 22, 20268-K Entered a material agreement; Other events65
  4. Sep 17, 20268-K Change to shareholders' rights; Bylaws or fiscal year changed66
  5. Jun 29, 20268-K Other events67
  6. May 26, 20268-K Other events68
  7. May 18, 20268-K Other events69
  8. Apr 15, 20268-K Listing notice or transfer70
  9. Mar 2, 20268-K Other events71
  10. Jan 8, 20268-K Ended a material agreement; Change to shareholders' rights; Other events72
  11. Dec 23, 20258-K Other events73
  12. Aug 20, 20258-K Other events74
  13. Jul 7, 2025New chief executive Holger Weis becomes CEO13
  14. Jan 23, 2024New chief executive Dale Curtis Hogue Jr. becomes CEO14
  15. Aug 31, 2021New chief executive Kevin S. Boyle Sr. becomes CEO16
  16. Mar 8, 2021New chief executive Heidi Hagen becomes CEO15
  17. May 7, 2015New chief executive Laurence James Neil Cooper becomes CEO17
  18. Nov 9, 2005Went public Listed on NASDAQ1
  19. Jan 1, 2005Founded Founded1

Calendar

Coming up

  1. Nov 13, 2026Reports results for the quarter ending Sep/202675

When it reported results

  1. Oct 10, 2024Reported quarterly or annual results76
  2. Nov 14, 2023Reported quarterly or annual results77
  3. Aug 14, 2023Reported quarterly or annual results78
  4. May 10, 2023Reported quarterly or annual results79
  5. Mar 7, 2023Reported quarterly or annual results80
  6. Nov 14, 2022Reported quarterly or annual results81
  7. Aug 15, 2022Reported quarterly or annual results82
  8. May 16, 2022Reported quarterly or annual results83

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

251 filings to the SEC since October 2021: 7 annual reports, 15 quarterly reports, 75 major events, 89 insider forms, 27 large holders, 38 other. The latest 20:

  1. Oct 15, 20263 EDGAR
  2. Oct 15, 2026SCHEDULE 13D EDGAR
  3. Oct 15, 2026SCHEDULE 13D/A EDGAR
  4. Oct 13, 20268-K EDGAR
  5. Oct 9, 20268-K EDGAR
  6. Oct 8, 20264 EDGAR
  7. Oct 8, 20264 EDGAR
  8. Oct 8, 20264 EDGAR
  9. Oct 8, 20264 EDGAR
  10. Sep 22, 20268-K EDGAR
  11. Sep 21, 2026424B3 EDGAR
  12. Sep 17, 20268-K EDGAR
  13. Aug 14, 202610-Q EDGAR
  14. Aug 11, 20264 EDGAR
  15. Jul 27, 20264 EDGAR
  16. Jul 27, 20264 EDGAR
  17. Jul 27, 20264 EDGAR
  18. Jul 27, 20264 EDGAR
  19. Jul 6, 2026S-8 EDGAR
  20. Jul 2, 20264 EDGAR

The 251 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

7 open-market trades by officers, directors and large owners since October 2021: 4 buys and 3 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Dec 31, 2024Vieser JaimeDirectorSale3,000$2.01$6.0KForm 4
Sep 1, 2023Boyle Kevin S. Sr.Chief Executive OfficerSale68,014$0.14$9.5KForm 4
Nov 29, 2022Postma Robert WDirectorBuy750,000$0.65$487.5KForm 4
Nov 29, 2022Vieser JaimeDirectorBuy1,250,000$0.65$812.5KForm 4
Dec 22, 2021De Groot EleanorEVP, OperationsSale20,132$1.27$25.6KForm 4
Nov 17, 2021Boyle Kevin S. Sr.Chief Executive OfficerBuy9,116$1.40$12.8KForm 4
Nov 16, 2021Boyle Kevin S. Sr.Chief Executive OfficerBuy884$1.40$1.2KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2024Melinda Lackey48$3.1K$430.4K96
2024Kevin S. BoyleSr.$317.5K$392.5K96
2024Dale Curtis HogueJr.56$234.0K$308.3K96
2024Ferdinand Groenewald40$3.1K$162.3K96
2023Former ChiefExecutive Officer$617.8K$2.0M96
2023Legal & AdministrationCorporate Secretary$312.1K$831.7K96
2023Drew Deniger$317.8K$733.4K96
2023Interim ChiefExecutive Officer$11.1K$48.2K96

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 29. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.21,353$48.3K0.0%No change
Geode Capital Management, LLC19,356$43.8K0.0%−3,204
Vanguard Fiduciary Trust Co15,497$35.0K0.0%No change
Vanguard Capital Management LLC14,063$31.8K0.0%No change
Citadel Advisors LLC11,870$26.8K0.0%+1,351
Osaic Holdings, Inc.1,731$3.9K0.0%−48
Tower Research Capital LLC (TRC)1,621$3.7K0.0%+38
Arax Advisory Partners1,216$2.7K0.0%New
UBS Group AG992$2.2K0.0%−1,282
Morgan Stanley836$1.9K0.0%+183
Vanguard Global Advisers, LLC501$1.1K0.0%No change
Royal Bank Of Canada375$1.0K0.0%+190
Wells Fargo & Company/mn388$8770.0%+198
Blue Trust, Inc.135$3050.0%No change
Steward Partners Investment Advisory, LLC112$2530.0%+20
Federation des caisses Desjardins du Quebec70$1580.0%No change
Bokf, Na66$1490.0%New
Axiom Investment Management LLC46$1040.0%New
Key Financial Inc24$540.0%No change
Signaturefd, LLC23$520.0%No change
NFSG Corp21$470.0%No change
Lanark Financial, Inc.20$450.0%No change
AdvisorNet Financial, Inc19$430.0%No change
Barclays PLC15$340.0%New
West Paces Advisors Inc.10$230.0%New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How ZIOPHARM Oncology is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARAlaunos Therapeutics, Inc.2
  • CIK0001107421
  • Employer ID (EIN)84-14756424
  • Filer statusNon- accelerated filer not an emerging growth company; a smaller reporting company; not a shell company4
  • Incorporated inDelaware4
  • Fiscal year endsDecember 312
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
  • Business address501 E Las Olas Blvd, Suite 300, Fort Lauderdale, FL 333012
  • Phone(346) 355-40992
  • Shares outstanding2,540,480 as of Aug 14, 202612
  • Public float$9.6M as of Jun 30, 20254
  • AuditorCherry Bekaert LLP, Tampa, Florida PCAOB ID 677; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceFeb 13, 20012
  • Filings1,294 in all: 4 (405), 8-K (352), 10-Q (56), 3 (53), SC 13G/A (52), SC 13G (35), DEFA14A (32), DEF 14A (21)2
    All 61 form types

    10QSB (20), 424B3 (19), 10-K (18), 424B5 (18), UPLOAD (18), DFAN14A (16), CORRESP (15), S-8 (13), SC 13D/A (12), EFFECT (10), S-3 (10), D (8), PRE 14A (8), 10KSB (7), S-3/A (7), 10-K/A (6), 8-K/A (6), CT ORDER (6), SCHEDULE 13D/A (6), 4/A (5), 10SB12G/A (4), SC 13D (4), SCHEDULE 13D (4), 10-Q/A (3), PRRN14A (3), 144 (2), 424B7 (2), ARS (2), DEFC14A (2), FWP (2), NT 10-K (2), NT 10-Q (2), POS AM (2), PREC14A (2), REGDEX (2), S-3ASR (2), SB-2 (2), SCHEDULE 13G/A (2), SEC STAFF LETTER (2), 10KSB/A (1), 10SB12G (1), 3/A (1), 424B8 (1), 5 (1), 8-A12B (1), CERTNAS (1), DFRN14A (1), PRER14A (1), S-1 (1), S-3MEF (1), SB-2/A (1), SC 14F1 (1), SCHEDULE 13G (1)

  • Latest filingsAnnual report (10-K) Mar 31, 2026
    Quarterly report (10-Q) Aug 14, 2026
    Proxy statement (DEF 14A) May 21, 2025
    Latest 8-K (8-K) Oct 13, 2026

Securities registered for trading

ClassSymbolExchange
Common StockTCRTThe Nasdaq

From the cover page of the 10-K filed Mar 31, 2026 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks ZIOPHARM Oncology names in Item 1A of its 10-K filed Mar 31, 2026: 39 risks under these headings, as written.4

  • RISKS RELATED TO OUR REPRIORITIZATION, FINANCIAL POSITION AND CAPITAL REQUIREMENTS
  • *Our strategic reprioritization to progress our Obesity and Metabolic Program may not be successful, may not yield the desired results and we may be unsuccessful in identifying and implementing any alternate strategic transaction.
  • *We will require substantial additional financial resources to continue as a going concern and to advance our Obesity and Metabolic Program, and if we raise additional funds, this may materially and negatively affect the value of your investment in our common stock.
  • We have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future.
  • Raising additional capital in the future may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to product candidates or our technology. In addition, the issuance of shares of common stock upon the exercise of our outstanding prefunded warrants or common stock warrants will result in immediate and substantial dilution to our existing stockholders.
  • If we are unable to successfully advance our obesity and metabolic disorders program or raise sufficient additional capital, our Board of Directors may ultimately decide to pursue a dissolution and liquidation.
  • RISKS RELATED TO OUR BUSINESS
  • * We are currently deficient under Nasdaq’s stockholders’ equity continued listing requirement and remain at risk of delisting, which could materially harm our liquidity, stock price, and ability to consummate strategic transactions.
  • *We have identified a material weakness and may identify more in the future or otherwise fail to maintain an effective system of internal controls, which may result in material misstatements of our financial statements or could have a material adverse effect on our business and trading price of our securities.
  • We have no products approved for commercial sale and have not generated any revenue from product sales. We may never generate any revenue from product sales or become profitable and, if we achieve profitability, we may not be able to sustain it.
  • Our obesity program is in an early preclinical stage and faces significant risks as we progress through additional animal studies and pursue a pathway to conducting IND enabling studies. We may never be able to advance the program to an IND filing, commercialize any product candidate, generate significant revenues, or attain profitability.
  • Our business is highly dependent on the success of our Obesity and Metabolic Disorders Program, which is in the early stages of development and will require significant additional preclinical and clinical development before we can seek regulatory approval for and commercially launch a product.
The other 29 risks
  • Preclinical development is uncertain. Our preclinical programs may experience delays or may never advance to clinical trials, which would adversely affect our ability to obtain regulatory approvals or commercialize these programs on a timely basis or at all, which would have an adverse effect on our business.
  • *Our reliance on third parties to formulate, manufacture and perform preclinical assays on our product candidates exposes us to a number of risks that may delay the development, regulatory approval and commercialization of our products or result in higher product costs.
  • We face competition from entities that have developed or may develop programs for the medical needs we plan to address with our Obesity and Metabolic Disorders Program.
  • Our operating history makes it difficult to evaluate our business and prospects.
  • Our business subjects us to the risk of liability claims associated with the use of hazardous materials and chemicals.
  • We may incur substantial liabilities and may be required to limit commercialization of our products in response to product liability lawsuits.
  • Our legacy TCR-T cell therapy programs and related intellectual property are no longer in active development and may not generate any meaningful value.
  • *Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.
  • Our ability to advance our Obesity and Metabolic Disorders Program depends on our ability to retain our remaining employee and consultants.
  • Any future growth would impose significant added responsibilities on members of management, including the need to identify, recruit, maintain and integrate additional employees.
  • We may become involved in litigation, including securities class action litigation, that could divert management’s attention and harm the Company’s business, and insurance coverage may not be sufficient to cover all costs and damages.
  • * Artificial intelligence and other advanced technologies used by us, our employees, consultants, or business partners may expose us to significant risks, including the loss or unauthorized disclosure of confidential information, intellectual property, or clinical and preclinical data, while the rapidly evolving regulatory and legal landscape surrounding artificial intelligence could materially and adversely affect our business.
  • *Cybersecurity incidents or IT failures could compromise sensitive information, disrupt operations, or reduce the value of our assets and impair our strategic alternatives.
  • RISKS RELATED TO OUR INTELLECTUAL PROPERTY
  • If we or our licensors fail to adequately protect or enforce our intellectual property rights or secure rights to patents of others, the value of our intellectual property rights would diminish and our ability to successfully develop our product candidates may be materially impaired.
  • If we are unable to protect the confidentiality of our confidential information, our business and competitive position would be significantly harmed.
  • Third-party claims of intellectual property infringement would require us to spend significant time and money and could prevent us from developing or commercializing our products.
  • Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.
  • We may be subject to claims by third parties asserting that our employee or we have misappropriated their intellectual property or claiming ownership of what we regard as our own intellectual property.
  • RISKS RELATED TO STOCK OWNERSHIP IN OUR COMPANY AND OTHER RISKS
  • Our stock price has been, and may continue to be, volatile.
  • Anti-takeover provisions in our charter documents and under Delaware law may make an acquisition of us, which may be beneficial to our stockholders, more difficult.
  • Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
  • Because we do not expect to pay dividends, you will not realize any income from an investment in our common stock unless and until you sell your shares at a profit.
  • Our ability to use net operating loss carryforwards and research tax credits to reduce future tax payments may be limited or restricted.
  • If securities' and/or industry analysts' recommendations change adversely or if our business, financial condition, results of operations, cash flows or prospects do not meet their expectations, our stock price and trading volume could significantly decline.
  • Our business could be materially and negatively affected as a result of the actions of activist stockholders.
  • Our principal stockholders, executive officers and directors have substantial control over the Company, which may prevent you and other stockholders from influencing significant corporate decisions and may significantly harm the market price of our common stock.
  • We are a “smaller reporting company,” and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors.
  • *We have issued preferred stock, and future issuances of preferred stock could adversely affect the rights of holders of our common stock.
  • *Ineffective investor relations and public relations efforts could harm our reputation, stock price, and ability to attract capital or strategic partners.

Legal proceedings

In the ordinary course of business, we may periodically become subject to legal proceedings and claims arising in connection with ongoing business activities. The results of litigation and claims cannot be predicted with certainty, and unfavorable resolutions are possible and could materially affect our business, financial condition, results of operations, cash flows and prospects. In addition, regardless of the outcome, litigation could have a material and adverse impact on us because of defense costs, diversion of management resources and other factors.

We do not have any pending litigation that, separately or in the aggregate, would, in the opinion of management, be reasonably likely to have a material adverse effect on our business, financial condition, results of operations, cash flows or prospects.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
    SEC EDGAROther events
  68. 68
    SEC EDGAROther events
  69. 69
    SEC EDGAROther events
  70. 70
  71. 71
    SEC EDGAROther events
  72. 72
  73. 73
    SEC EDGAROther events
  74. 74
    SEC EDGAROther events
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80
  81. 81
  82. 82
  83. 83
  84. 84
  85. 85
  86. 86
  87. 87
  88. 88
  89. 89
  90. 90
  91. 91
  92. 92
  93. 93
  94. 94
  95. 95
  96. 96